Loading filters...
Publications per Year (1031 total)
31
1990
29
·
44
·
31
·
32
·
26
1995
29
·
35
·
21
·
40
·
42
2000
36
·
45
·
52
·
63
·
42
2005
7
·
12
·
15
·
15
·
11
2010
21
·
16
·
22
·
20
·
18
2015
24
·
22
·
28
·
30
·
23
2020
28
·
28
·
27
·
30
·
22
2025
14
·
Loaded
Click to load
50 / 1031 papers loaded(scroll for more)
20267 papers
First-line IOAdvanced/Metastatic2026
Distinct pathways of disease progression with dual checkpoint blockade versus immunotargeted therapy in metastatic renal cell carcinoma.
Tsimafeyeu I et al. Urol Oncol. 2026
First-line IOAdvanced/Metastatic2026
Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study.
Blanchet B et al. Br J Cancer. 2026
GeneralAll Stages2026
Venous invasion in upper tract urothelial carcinoma: Diagnostic features and oncologic outcomes.
Brönimann S et al. Urol Oncol. 2026
TKIAdvanced/Metastatic2026
Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study.
Shah NJ et al. Urol Oncol. 2026
TKIearly2026
HIF-2α Inhibitor Combinations Knock Back Kidney Cancer in Two Trials.
Cancer Discov. 2026
First-line IOAdvanced/Metastatic2026
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.
Choueiri TK et al. Ann Oncol. 2026
First-line IOAdvanced/Metastatic2026
CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor-based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma.
Albiges L et al. Eur Urol. 2026
200540 papers
GeneralAdvanced/Metastatic2005
Re-evaluation of the Tumour-Node-Metastasis staging of locally advanced renal cortical tumours: absolute size (T2) is more significant than renal capsular invasion (T3a).
Murphy AM et al. BJU Int. 2005
GeneralAll Stages2005
Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma.
Dudderidge TJ et al. Clin Cancer Res. 2005
GeneralAll Stages2005
Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a?
Thompson RH et al. J Urol. 2005
GeneralAll Stages2005
Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort.
Frank I et al. J Urol. 2005
GeneralAll Stages2005
Long-term outcome of nephron sparing surgery and simple nephrectomy for unilateral localized Wilms tumor.
Zani A et al. J Urol. 2005
GeneralAll Stages2005
Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved?
Leibovich BC et al. J Urol. 2005
GeneralAll Stages2005
Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy.
Desai MM et al. J Urol. 2005
Generalearly2005
Current clinical trials in renal cell carcinoma.
Sokoloff MH et al. Urol Oncol. 2005
GeneralAdvanced/Metastatic2005
Long-term survival analysis after laparoscopic radical nephrectomy.
Permpongkosol S et al. J Urol. 2005
GeneralAll Stages2005
Progression and long-term survival after simple enucleation for the elective treatment of renal cell carcinoma: experience in 107 patients.
Lapini A et al. J Urol. 2005
cytokineAll Stages2005
A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo.
Yuasa T et al. Clin Cancer Res. 2005
GeneralAdvanced/Metastatic2005
A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC et al. J Urol. 2005
GeneralAll Stages2005
Partial nephrectomy with perfusion cooling for imperative indications: a 24-year experience.
Steffens J et al. BJU Int. 2005
GeneralAll Stages2005
The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer.
Kuczyk M et al. Eur Urol. 2005
GeneralAll Stages2005
Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features, surgical techniques and outcomes.
Parekh DJ et al. J Urol. 2005
GeneralAll Stages2005
pT1 substaging in renal cell carcinoma: validation of the 2002 TNM staging modification of malignant renal epithelial tumors.
Salama ME et al. J Urol. 2005
GeneralAll Stages2005
Intermediate followup of hand assisted laparoscopic nephroureterectomy for urothelial carcinoma: factors associated with outcomes.
Wolf JS et al. J Urol. 2005
cytokineearly2005
Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J et al. Br J Cancer. 2005
cytokineAdvanced/Metastatic2005
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
McDermott DF et al. J Clin Oncol. 2005
GeneralAll Stages2005
Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma.
Sandhu SS et al. BJU Int. 2005
cytokineAdvanced/Metastatic2005
Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
Aass N et al. J Clin Oncol. 2005
cytokineAdvanced/Metastatic2005
Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma.
Donskov F et al. Br J Cancer. 2005
cytokineAll Stages2005
Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy.
Verra N et al. Eur Urol. 2005
GeneralAll Stages2005
Associations with contralateral recurrence following nephrectomy for renal cell carcinoma using a cohort of 2,352 patients.
Bani-Hani AH et al. J Urol. 2005
cytokineAdvanced/Metastatic2005
C-jun activation in acquired cystic kidney disease and renal cell carcinoma.
Oya M et al. J Urol. 2005
cytokineAdvanced/Metastatic2005
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.
Zea AH et al. Cancer Res. 2005
cytokineAll Stages2005
Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma.
Jöhrer K et al. Clin Cancer Res. 2005
cytokineAll Stages2005
A spliced isoform of interleukin 6 mRNA produced by renal cell carcinoma encodes for an interleukin 6 inhibitor.
Alberti L et al. Cancer Res. 2005
cytokineAdvanced/Metastatic2005
Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.
Frankenberger B et al. Clin Cancer Res. 2005
cytokineAdvanced/Metastatic2005
C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Casamassima A et al. J Urol. 2005
TKIAdvanced/Metastatic2005
Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
Hainsworth JD et al. J Clin Oncol. 2005
GeneralAll Stages2005
Renal oncocytoma: a clinicopathological analysis of 45 consecutive cases.
Gudbjartsson T et al. BJU Int. 2005
GeneralAdvanced/Metastatic2005
Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens.
Minardi D et al. J Urol. 2005
GeneralAdvanced/Metastatic2005
Prognostic significance of clinicopathologic and deoxyribonucleic acid flow cytometric variables in non-metastatic renal cell carcinoma in the modern era.
Clark PE et al. Urol Oncol. 2005
GeneralAll Stages2005
Management of isolated renal fossa recurrence following radical nephrectomy.
Master VA et al. J Urol. 2005
GeneralAdvanced/Metastatic2005
The impact of provider volume on outcomes from urological cancer therapy.
Joudi FN et al. J Urol. 2005
cytokineAll Stages2005
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
Atkins M et al. Clin Cancer Res. 2005
GeneralAll Stages2005
Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses.
Gillett MD et al. J Urol. 2005
GeneralAdvanced/Metastatic2005
Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma.
Kim HL et al. J Urol. 2005
cytokineAll Stages2005
Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens.
Amato RJ et al. Ann Oncol. 2005
20063 papers
GeneralAdvanced/Metastatic2006
Reassessing the current TNM lymph node staging for renal cell carcinoma.
Terrone C et al. Eur Urol. 2006
cytokineAdvanced/Metastatic2006
Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study.
Bex A et al. Eur Urol. 2006
GeneralAll Stages2006
Elective nephron sparing surgery should become standard treatment for small unilateral renal cell carcinoma: Long-term survival data of 216 patients.
Becker F et al. Eur Urol. 2006